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Search Strategy and selection criteria 
References for this review were identified through searches of PubMed for articles 
published from January, 1980, to June, 2016, by use of the terms "pneumocystis, PCP, P. 
carinii, P. jirovecii, cryptococcal meningitis, cryptococcosis, C. neoformans, C. gattii, 
histoplasmosis, Histoplasma capsulatum, Penicillium marneffei, penicilliosis, 
Talaromyces marneffei, talaromycosis, fungal infection, mycoses AND (HIV OR 
AIDS)", Relevant articles prior to these dates and abstracts were identified through 
searches in the authors' personal files. Articles resulting from these searches and relevant 
references cited in those articles were reviewed. Articles published in English, French, 
and Spanish were included. 
 
Key Points  
 Although the incidence of systemic fungal infections in HIV-infected patients has 
decreased in many resource-rich areas following introduction of antiretroviral 
therapy and earlier diagnosis and treatment of HIV infection, in many resource-
limited settings this incidence is not yet decreasing due to continued late diagnosis 
and challenges with retention in HIV care. 
 New PCR-based assays can distinguish colonization from infection with 
Pneumocystis. 
 Measurement of CSF pressure is essential in cryptococcal meningitis, and 
management of raised CSF pressure through careful therapeutic lumbar punctures 
reduces mortality 
 In large parts of the world, HIV-related histoplasmosis is often neglected, 
undiagnosed, or misdiagnosed as tuberculosis, due to lack of access to current 
diagnostics. 
 Talaromycosis (formerly penicilliosis) is the second most common bloodstream 
infection in AIDS patients in Vietnam. Patients present very late in the illness 
with significant on-treatment morbidity and mortality. A large randomized trial 
comparing amphotericin B and itraconazole as initial treatments will report soon. 
 Novel, affordable, point-of-care diagnostics for pneumocystis, histoplasmosis, 
and talaromycosis, and wider access to effective antifungals are urgently needed 
to reduce the burden of HIV-associated fungal infections in resource-limited 
settings. 
  
Abstract 200 words 
Fungi are major contributors to the opportunistic infections that threaten patients with 
AIDS. Pneumocystis jirovecii is the commonest respiratory infection and Cryptococcus 
neoformans the commonest central nervous system infection in AIDS patients across 
large parts of the world. Histoplasma capsulatum and Talaromyces (Penicillium) 
marneffei are thermally dimorphic fungi that cause disseminated infections, the former 
being especially common in parts of the Americas, and the latter endemic in SE Asia.  
 
With widespread availability of ART and earlier testing for HIV, the incidence of 
systemic fungal infections has decreased in HIV-infected persons in the developed world. 
But, importantly, in many areas of high HIV prevalence, many patients continue to 
present late with a low CD4 cell count or re-present with persistent low CD4 cell counts 
due to problems of adherence and or ART resistance. For pneumocystosis, talaromycosis, 
and in particular histoplasmosis, affordable, rapid point-of-care diagnostic tests, as have 
been developed for cryptococcosis, are urgently needed. In addition, antifungal drugs, 
including amphotericin B, liposomal amphotericin B, and flucytosine, need to be made 
much more widely available. Such measures, together with continued international efforts 
in education and training in the management of fungal disease, have the potential to 
significantly improve patient outcomes. 
 
Introduction 
 
Fungi are major contributors to the opportunistic infections that threaten patients with late 
stage HIV infection. Pneumocystis jirovecii is the commonest respiratory infection and 
Cryptococcus neoformans the commonest central nervous system infection in AIDS 
patients across large parts of the world. Histoplasma capsulatum and Talaromyces 
(formerly Penicillium) marneffei are thermally dimorphic fungi that cause disseminated 
infections, the former being widespread, although especially common in the Americas, 
and the latter endemic in SE Asia. Herein, we review the epidemiology and progress in 
diagnosis and therapy for these major systemic fungal pathogens seen in HIV patients. In 
addition, Coccidioides sp. and Emmonsia sp. are significant pathogens in AIDS patients 
in the Americas and South Africa respectively 1,2. Candida species commonly cause 
mucosal, oral, vaginal and oesophageal infections in those with stage 3 and 4 HIV 
disease, and fungal skin and nail infections are major causes of morbidity in HIV-infected 
individuals. Fortunately, mucosal candida infections usually respond readily to azole 
therapy and immune reconstitution with antiretroviral therapy (ART), and, in the era of 
ART, recurrent azole resistant Candida infections are rare. 
 
With widespread availability of ART and earlier testing and treatment for HIV, the 
incidence of systemic fungal infections has decreased in persons living with HIV in the 
developed world, although room for improvement still remains3S. However, importantly, 
in many areas of high HIV prevalence, particularly in Sub-Saharan Africa, there is as yet 
little evidence for a significant decline in cases 4S . Many patients continue to present late 
with a low CD4 cell count 5S . In addition, as enrolment data for recent cryptococcal 
meningitis trials shows, while there is no decline in the total number of cases, half or 
more of cryptococcal patients are now ART-experienced 6S  but with persistent low CD4 
cell counts due to problems of retention in care and or ART resistance. Thus, further 
efforts to address the problem of fungal infections through rapid point-of-care diagnostics 
for these major fungal pathogens and global access to antifungal drugs are needed, as an 
integral part of an effective response to the HIV pandemic. 
 
Pneumocystis Pneumonia  
 
Pneumocystis pneumonia has emerged as a major cause of infection in those with 
HIV/AIDS, with an estimate of >400,000 cases worldwide annually.7 Many of these 
patients are unfortunately undiagnosed or diagnosed late particularly in resource-limited 
settings. The mortality of Pneumocystis pneumonia ranges from 10 to 30% or higher, 
depending on the patient population, comorbidities, and whether the diagnosis is made 
early enough.8,9 While the incidence has been reduced by implementation of ART, 
Pneumocystis continues to be a problem in patients who are unaware that they are HIV-
infected, and in those that fail or default from ART.10  
 
Pathogenesis: Pneumocystis species are members of the Ascomycetous fungiS . Each 
mammalian species may harbor at least one unique species of the Pneumocystis genus,11 
for example, Pneumocystis jirovecii infecting humans and  Pneumocystis carinii infecting 
rats. Serological and epidemiological data indicate that most humans are exposed and 
transiently infected with Pneumocystis early in life.12 With normal immune responses, 
this early infection is effectively cleared. However, during periods of immune 
suppression such as in HIV-infected patients with CD4 cell counts <200/L, the 
organism proliferates leading to life-threatening pneumonia.  CD4 immunity is absolutely 
essential for long-term control and memory responses to this fungus, with contributing 
immunity provided by innate immune responses, CD8 cells, and B-lymphocytesS. In the 
absence of effective CD4-based immunity, innate inflammatory responses promote the 
accumulation of inflammatory cells including neutrophils and CD8 lymphocytes, which 
strongly contribute to lung injury. Appreciation of this exuberant innate immune response 
has led to the use of adjunctive anti-inflammatory corticosteroids in moderate to severe 
Pneumocystis pneumonia.13 Current evidence suggests that Pneumocystis can be acquired 
from other infected individuals. Therefore, whenever feasible, immunosuppressed 
patients should not be directly exposed to individuals with active Pneumocystis 
pneumonia.14,15 
 
Diagnosis:  Most patients with Pneumocystis pneumonia present with cough and 
progressive dyspnea, initially on exertion, and pulmonary infiltrates on CXR or lung 
imaging (Figure 1A).  Definitive diagnosis relies on identification of Pneumocystis 
jirovecii organisms in respiratory secretions or bronchoalveolar lavage samples (Figure 
1B). Skilled observers can identify the organisms using Wright Giemsa stained smears.  
However, tinctorial methods including methenamine silver, Papanicolau, cresyl echt 
violet, and Calcofluor white staining significantly assists in rapid identification of 
organisms.16 Fluorescence staining with monoclonal antibodies further increases yield to 
approximately 95% when applied to BAL samples.9  
 
Over the past decade, a number of laboratories have switched to identification using 
PCR. Nested PCR has been useful to identify colonization as well as clinical infection, 
whereas, single copy real-time PCR assays have been devised to rapidly identify patients 
with clinical infection, rather than colonization.17,18 There remains a pressing need for 
inexpensive point-of-care diagnostic strategies, which are technically less demanding, 
that can be applied in regions with limited resources,7  and work is ongoing to develop 
relevant Pneumocystis antigen detection systems and thermocycler independent 
amplification strategies that may be utilized in such settings to facilitate diagnosis.  
 
Beta D-glucan assays in the serum can be useful as a screening tool and adjunct to 
diagnosis, since it has good sensitivity in patients with HIV and Pneumocystis 
pneumonia.  Although Beta D-glucan testing does cross react with the glucans released 
from other fungi, high levels of Beta-D Glucan (>100 pg/ml) in HIV infected patients 
with the appropriate clinical scenario does provide evidence to support initiating 
therapy.19 
 
Vast regions of the world including sub-Saharan Africa, Asia, and South America lack 
ready access to laboratory facilities equipped for the diagnosis of Pneumocystis 
pneumonia, rendering the true burden and impact of this infection under-recognized. For 
instance, unsuspected Pneumocystis infection was found to be the cause of up to 7% of 
all severe pneumonia in children under age five in Mozambique, when modern diagnostic 
methods were applied.20  In regions with limited laboratory facilities, the diagnosis of 
Pneumocystis is often made on clinical grounds.  While such an approach is pragmatic, it 
lacks specificity, which is necessary to rapidly focus the appropriate antibiotic therapy 
towards Pneumocystis when it is present.  
 
Therapy:  The mainstay of therapy has long been intravenous sulfamethoxazole-
trimethoprim (TMP-SMX) with the trimethoprim component dosed at 15-20 mg/kg/day 
and sulfamethoxazole at 75-100 mg/kg/day.  This is given in four equally divided doses 
for 21 days.  For patients with milder disease, and once the disease is under control, 
therapy can be safely switched from IV to oral administration. It is useful to monitor 
therapeutic trough levels to avoid toxicity and ensure benefit, though infrequently done.13 
Often, clinical improvement is not observed for up to one week.  Patients who cannot 
tolerate TMP-SMX are usually treated with the combination of primaquine and 
clindamycin or pentamidine.  Atovaquone is generally reserved for those with milder 
disease.13 Of note, efavirenz significantly reduces atovaquone concentrationsS. Only 
TMP-SMX is currently present on the WHO Essential Medicine List for Pneumocystis 
pneumonia, with the alternatives appearing on the complementary list and for other 
indications.  
 
Adjunctive corticosteroid therapy is given to patients with moderate to severe 
Pneumocystis pneumonia, as evidenced by a room air PaO2 < 70 mmHg or alveolar-
arterial oxygen gradient of >35 mmHg. For these individuals, prednisone is provided at 
40 mg twice daily on days 1-5, 40 mg once daily on days 6-10, then 20 mg once daily to 
day 21.21 In paediatric populations, prednisone may be given at 1 mg/kg twice daily on 
days 1-5, 0.5 mg/kg twice a day on days 6-10; and finally 0.5 mg/kg once daily on days 
11-21.22  
 
Prevention:  Appropriate Pneumocystis prophylaxis is essential for preventing this often-
lethal infection. HIV-infected patients who have CD4 counts <200/ microliter, or with a 
history of oropharyngeal candidiasis, should receive prophylaxis with one double 
strength TMP-SMX tablet thrice weekly, or one single strength TMP-SMX tablet once a 
day.23 TMP/SMX in the developing world has additional benefits, reducing early 
mortality from malaria, reducing anemia and improving growth in children.24 
Alternatives for patients that cannot tolerate TMP/SMX include dapsone, atovaquone, or 
dapsone with pyrimethamine and leucovorin.13 Dapsone should be use cautiously in 
individuals with G6PD deficiency.13 In general, prophylaxis can be discontinued when 
CD4 counts are consistently >200 cells/microliter for greater than three months. An 
effective Pneumocystis vaccine is not yet available, but pre-clinical primate studies 
support the potential efficacy of such an approach for HIV-infected patients.25  
 
Cryptococcosis 
 
Latest estimates suggest that HIV-associated cryptococcal meningitis accounts for 
150,000-200,000 deaths per year mostly in Sub-Saharan Africa, where the associated 
mortality remains around 70% at 3 monthsS. Most HIV-associated infections are caused 
by C. neoformans although in Botswana, up to 30% are C. gattiiS. Patients present with 
headache and fever, with a median duration of 2 weeks 26. Many patients develop nausea, 
vomiting, diplopia due to 6th nerve palsies, and reduced visual acuity related to raised 
cerebrospinal fluid (CSF) pressure. Untreated, symptoms progress to abnormal mental 
status, reduced conscious level, seizures, and finally coma.  
 
Diagnosis. Traditionally diagnosis has relied on lumbar puncture (LP). A CSF India Ink 
preparation is positive in 70-90% of HIV-associated cases 26, and the remainder of 
patients can be reliably diagnosed by cryptococcal antigen (CrAg) detection or culture. 
However, headache is non-specific and LP is frequently delayed, especially in resource-
limited settings, until such time as the prognosis is poor. In this context, development of a 
point-of-care lateral flow test for detection of CrAg is a major advance 27. Antigen is 
present in blood (serum, plasma or whole blood finger-prick sample) prior to the 
development of symptoms and the test is highly specific and more sensitive than prior 
latex agglutination assaysS. The test enables earlier diagnosis, even in primary care 
settings, and screening of medical in-patients in high prevalence areas. It also makes 
feasible screening and pre-emptive therapy as a strategy to prevent the development of 
meningitis after HIV diagnosis and prior starting ART in those with low CD4 cell counts 
28.  
 
Antifungal therapy. Gold standard antifungal therapy remains the combination of 
amphotericin B deoxycholate (D-AmB), 0.7-1 mg/kg/d, plus flucytosine (100 mg/kg/d in 
4 divided doses), for the initial 2 weeks, followed by fluconazole 400-800 mg/d for 8 
weeks, and 200 mg/d thereafter for a minimum of one year and until immune 
reconstitution 29-31. Addition of flucytosine was associated with a 40% reduction in 
mortality compared with D-AmB alone 32. Pre-hydration with Normal saline and pre-
emptive replacement of potassium and magnesium is recommended to mitigate the 
toxicities of D-AmB 30, but anaemia remains a significant problem where transfusion 
capacity is limited. Liposomal amphotericin B (Ambisome. L-AmB) at 3-6 mg/kg/d is as 
effective and better tolerated than D-AmB 33. Studies are ongoing to determine if it could 
be used in intermittent high doses, as in leishmaniasisS, to provide a convenient and cost 
effective induction treatment. Of note, with care to adjust doses in case of renal 
impairment, flucytosine is generally well-tolerated in this patient population for 2 weeks 
34.  
 
Complications. Raised CSF pressure caused by a blockage of CSF reabsorption at the 
level of the arachnoid granulations is common with around a quarter of patients having a 
pressure of >35 cm 35. Untreated, high pressure is associated with increased mortality 35, 
but increasing evidence points to the effectiveness of careful therapeutic lumbar 
punctures 26,36,37. Only the most severe cases may require a temporary lumbar drain or 
ventricular shunt 38,39. Importantly, high CSF pressure may develop in the second and 
third weeks of treatment, despite effective sterilization of the CSF, meaning that an LP 
should be repeated if symptoms persist or recur. 
 
Current recommendations are to start ART between 4 and 6 weeks after starting 
antifungal therapy, based on studies suggesting 3 days and 8 days is too soon 40,41, and 6 
weeks or later, probably unnecessarily lateS. Of importance given that in many centres 
half of cryptococcal meningitis cases now occur in ART-experienced patients, it is 
prudent to also only switch to second line ART in those thought to have ART resistance, 
or re-start ART in those who have discontinued taking ART, after 4 weeks of antifungal 
therapy. Of note, these cases of cryptococcal meningitis in patients failing ART need to 
be distinguished from unmasking cryptococcal immune reconstitution inflammatory 
syndrome (CM-IRIS) cases 42S whose presentation is precipitated by starting ART, and in 
whom ART should be continued. Frequent clinical review is needed given some 
overlapping toxicities of antifungal and antiretroviral drugs.  
 
Paradoxical CM-IRIS occurs in 15-20% of cases. These patients respond to treatment but 
later have a recurrence of symptoms, at a median of around one month after starting ART 
43S. In patients representing with a recurrence of symptoms, CSF pressure should be 
measured and managed, as raised pressure is common in CM-IRIS. Re-introduction of 
induction antifungal therapy may be considered pending CSF culture results, and while 
alternative diagnoses are actively pursued. If CM-IRIS remains the likely diagnosis, and 
the patient is deteriorating, then short courses of corticosteroids in this particular situation 
have been used successfully. In contrast, corticosteroids with initial antifungal therapy 
have been shown to be harmful 6. While CM-IRIS may be life-threatening, related 
mortality should be less than in earlier series, with increased awareness and prudent 
timing of ART. 
 
Prevention. The lateral flow CrAg test has made feasible a screen and pre-emptive 
fluconazole treatment strategy to prevent the development of meningitis in patients with 
low CD4 cell counts. The percentage of HIV-infected individuals with a CD4 cell count 
<100 who test positive on CrAg screening of blood samples usually ranges from 3 to 8% 
44S; and in a retrospective study from Cape Town, those testing positive had a high, 28%, 
chance, without treatment, of developing meningitis in the first year of ART, whereas, of 
those who tested negative and were started promptly on ART, none went onto develop 
meningitis 28. Subsequent modeling suggested such a strategy could be highly cost 
effective 44,45, and screening has been endorsed in WHO guidelines 30 and introduced in 
South Africa, and elsewhere. Prospective studies are underway, with one report 
demonstrating that such screening and pre-emptive fluconazole, combined with ART 
adherence support, led to a 28% reduction in mortality in late stage HIV patients in the 
first year of ART 46. Further work however, is needed to optimize the treatment of CrAg 
positive patients. Despite fluconazole, these patients still have higher mortality compared 
to those testing CrAg negative 46,47, and of some concern there have been reports of 
decreased susceptibility to fluconazole in some areas 48. A significant proportion of 
patients, even though asymptomatic or minimally symptomatic, have evidence of 
meningitis if they agree to an LP, and this risk is related to blood antigen titre 47. Studies 
are planned to determine if those with a high antigen titre in blood would benefit from 
more aggressive antifungal therapy. 
 
Histoplasmosis 
 Histoplasmosis is caused by Histoplasma capsulatum (Hc) a thermally dimorphic 
ascomycete 49. The mold form is distributed worldwide in moist and enriched soils 
containing bird or bat guano 50. Autochthonous cases of HIV-associated histoplasmosis 
have been described on five continents, the Americas accounting for most cases, notably 
the Central Eastern USA and Latin America 51. However, HIV-associated histoplasmosis 
is more widespread than previously thought and probably neglected, undiagnosed or 
mainly misdiagnosed as tuberculosis 52S. In endemic areas, histoplasmosis incidence 
ranges between 2-25% and represents the first AIDS-defining infection in up to 50-75% 
of HIV patients 53. Lethality rates range between 10-60% depending on whether the 
diagnosis is made by experienced physicians with adequate infrastructure and access to 
antifungals other than fluconazole 54,55. 
 
Pathogenesis: Soil disruption aerosolizes microconidia or mycelial fragments which are 
inhaled and, at body temperature, convert into yeasts in the lungs 50. Infection may also 
develop when, years after the primary infection, quiescent organisms are reactivated 
during immunosuppression.56S Once in the lungs, Hc survives phagocytosis in 
macrophages, facilitating its dissemination throughout the mononuclear phagocyte 
system. An early robust proinflammatory response (TH1/TH17) is required to control Hc 
growth 57. Hence, people living with HIV are at higher risk of disseminated 
histoplasmosis, an AIDS-defining condition, which is lethal if left untreated 50S. 
 
Environmental exposures to bird or bat guano and history of exposure to chicken coops 
are associated with an increased risk of histoplasmosis 58. Host factors such as low CD4 
count <200/mm3, nadir CD4 count <50/mm3, CD8 count <650/mm3, absence of ART or 
systemic antifungal therapy, the first 6 months of ART, history of Herpes simplex 
infection and male gender are independently associated with histoplasmosis in those with 
HIV infection 59. 
 
Clinical Features and Diagnosis: In AIDS, histoplasmosis usually presents as a 
disseminated disease (>95%). All organs and tissues may be involved. Fever, fatigue and 
weight loss are almost universal. Cough and dyspnea are the most frequent localizing 
symptoms, in association with diffuse radiologic infiltrates usually with a miliary 
reticulonodular pattern (Figure 2A) 53. Abdominal pain and diarrhea are frequent and 
reflective of colonic ulcerations (Figure 2C)S. Lymph node enlargement, 
hepatosplenomegaly, and muco-cutaneous manifestations are diagnostic clues 53. LDH, 
liver enzymes (TGO>TGP) and ferritin elevation with or without pancytopenia and/or 
hemophagocytosis syndrome should lead to further investigations 51. Classically subacute 
(1 to 2 months), the disease evolution varies from latency to 10-20% fulminant severe 
forms (“septic shock” with multiorgan failure), mainly in late presenters, with fatality 
rates reaching 50-70% 51,53. 
  
Direct examination with special staining (May-Grünwald Giemsa, PAS, and Grocott-
Gömöri methenamine-silver) and culture of all tissues or body fluids at room temperature 
are the Gold Standard methods for diagnosis 60. Bone marrow aspiration, blood culture 
and tissue biopsies are all useful 51. Direct examination is rapid but culture, which 
requires a BSL-3 laboratory, takes a median of 2 weeks, and up to 6 weeks. For both, 
sensitivity varies with sample type, disease severity and operator experience 51. Antibody 
detection is of most interest in CSF for the diagnosis of neuro-meningeal forms 61. 
Although useful molecular tools are being developed, their place in care and treatment is 
still evolving 51. Detection of Hc antigen is among the most sensitive and rapid means to 
diagnose disseminated histoplasmosis in AIDS 62. To date, the noninvasive reference 
method in the USA has been a polyclonal quantitative Histoplasma antigen 
radioimmunoassay in urine, blood and BAL, but it is unavailable in other endemic areas 
51. However, a new commercially available monoclonal EIA detecting galactomannan 
antigen in urine is being made widely available with promising results 62,63. It is 
noteworthy that the highest yield is achieved by combining several diagnostic methods. 
 
Therapy: In moderately severe to severe cases, i/v liposomal amphotericin B (3-4 
mg/kg/day) is recommended for two weeks or until clinical improvement64. An 
alternative lipid formulation of amphotericin B at the same dosage may be preferred over 
D-AmB (0.7mg/kg daily) if liposomal amphotericin is unavailable. Continued treatment 
with oral itraconazole (200mg three times daily for 3 days, followed by 200mg twice 
daily) is given for at least one year.64 Non-severe cases can be treated with itraconazole 
alone.64 Prevention is based on recommendations for workers at risk and long term 
suppressive therapy with itraconazole 200mg daily as primary (only in USA) or 
secondary prophylaxis 65S. ART should be started promptly, within the month following 
antifungal therapy initiation 64. Nevirapine and efavirenz are moderate inducers of the 
CYP3A4 enzyme, and have been shown to reduce the level of itraconazole 66. However, 
both itraconazole and its major metabolite hydroxyitraconazole are equally active 
antifungal agentsS, and it remains unclear whether itraconazole dose adjustment is 
needed. In view of these interactions, a randomly obtained serum level of at least >1.0 
µg/mL of itraconazole is recommended after 2 weeks of therapy 64,67.  
 
During the last decades, morbidity and mortality from histoplasmosis have increased, 
largely attributable to the spread of HIV 68. Although thousands are dying of a treatable 
disease, histoplasmosis is off the radar of international organizations involved in the fight 
against HIV/AIDS and tuberculosis 69. Hence, the global burden of histoplasmosis 
remains unknown and access to rapid and simple diagnostics and effective antifungals 
remains a challenge in low and middle income countries 69,70S.  
 
Talaromycosis (formerly penicilliosis)  
 
Epidemiology. Talaromyces marneffei causes a life-threatening mycosis affecting 
primarily immunocompromised residents and travelers in Southeast Asia, southern 
China, and northeastern India (Figure 3).71,72 The intersection with HIV has transformed 
T. marneffei from a rare human pathogen to a major cause of HIV-associated death, 
trailing only tuberculosis and cryptococcosis or Pneumocystis pneumonia in Thailand and 
Hong Kong.73,74 In Vietnam, talaromycosis makes up 4-11% of AIDS-related 
admissions75,76 and is the second most common cause of bloodstream infections after 
cryptococcosis.77 ART has led to a decline in incidence, but talaromycosis remains a 
major problem in undiagnosed and/or untreated HIV infection. Increasingly 
talaromycosis occurs outside endemic regions due to increased migration and 
international travel,78S and a rise in use of chemotherapy and immunosuppression.79S  
 
Ecology and transmission. Pathogen reservoirs and disease acquisition are being 
elucidated. The bamboo rat is the only non-human host of T. marneffei with a high 
frequency of asymptomatic infection.80,81 The isolates from bamboo rat and human have 
similar or identical genotypes.80,81 However, there is no evidence of direct bamboo-rat-to-
human transmission; instead occupational exposure to plants and animals has been 
associated with human infection.82 This association is recently confirmed in a large case-
control study from Vietnam, which additionally reveals that residents from or travelers to 
highland areas are at increased risk.83 Incidence increases 30%-50% during the rainy 
months,76,84 and can be predicted by humidity levels.85,86 T. marneffei has been isolated 
from bamboo-rat feces and soil samples within bamboo-rat burrows,87,88S and T. 
marneffei DNA detected in elephant-associated soil.89 Collectively, these epi-ecological 
data suggest an interplay amongst multiple environmental reservoirs involving soil, 
plants, and animals, in which bamboo rat may be exploited by T. marneffei to expand its 
biomass and biogeography. Human infections likely occur through inhalation of T. 
marneffei conidia. The incubation period is estimated to be 1-3 weeks in acute disease, 
whilst reactivation disease can occur many years after exposure in immunocompromised 
hosts.    
 
Clinical features and outcomes. The majority of infections occur in patients with CD4 
T-cell counts <100 cells/mm3. Patients typically develop disseminated disease with fever, 
weight loss, hepatosplenomegaly, lymphadenopathy, respiratory and gastrointestinal 
abnormalities. Papulonecrotic skin lesions are present in 60-70% of patients (Figure 4A). 
Common laboratory findings include anaemia, thrombocytopenia, and elevated 
transaminases. 71,75,76 Concomitant opportunistic infections are common, particularly 
tuberculosis and Salmonella infections.75,76S  
 
Case fatality rates in treated patients vary, from 10% in Thailand and Hong Kong71,90 up 
to 33% in China and Vietnam,76,85,91 reflecting differences in time to diagnosis and access 
to ART. Some clinical and laboratory predictors of mortality include older age, shorter 
duration of symptoms, dyspnea, absence of fever or skin lesions, thrombocytopenia, and 
elevated lactate dehydrogenase levels.75,76  
 
T. marneffei-associated IRIS has been reported, commonly as unmasking IRIS in patients 
starting ART. The skin lesions can be atypical including erythematous nodules, verrucous 
lesions, or erythematous plaques.92,93S Prospective studies that define incidence, risk, and 
impact of talaromycosis IRIS are lacking. Continuation of ART, antifungal therapy, and 
cautious use of non-steroidal anti-inflammatory medications are the main therapeutic 
approaches.  
 
Diagnosis. Presumptive diagnosis can be made based on microscopic findings of intra- 
and extra-macrophage yeast organisms in smears of skin lesions, lymph node or bone 
marrow aspirate (Figure 4B). Definitive diagnosis is made by pathogen isolation from 
clinical specimens demonstrating thermal dimorphism (Figure 4C). Culture can be slow 
(3-14 days), resulting in diagnostic delay and higher mortality particularly in patients 
without skin lesions.73,76S PCR-based assays have been developed for rapid 
diagnosis;94,95S however the sensitivities are insufficient (range 60-70%) to be considered 
widely applicable. Recently-developed enzyme-linked immunosorbent assays  detecting 
T. marneffei  antigen appear to be more sensitive than blood culture and other diagnostic 
methods,96,97 and should be further evaluated for clinical application. Point-of-care tests 
are urgently needed.   
 
Antifungal therapy and prevention. D-AmB and itraconazole are effective drugs, 
whilst T. marneffei is resistant to fluconazole,75,76,90,91. A multi-centre clinical trial 
comparing D-AmB and itraconazole induction therapy reported mortality after 6 months 
of 11.3% and 21.0%, respectively (absolute risk difference, 9.7%; 95% CI, 2.8% to 
16.6%; P=0.006)  (IVAP trial, registration ISRCTN97524945) [new citation at the end of 
the references]. Liposomal amphotericin B and voriconazole are also effective; however 
they are not available in resource-limited settings. International guidelines recommend D-
AmB (0.6-1.0mg/kg/day) for 2 weeks, followed by itraconazole 400mg/day for 10 weeks, 
with itraconazole 200mg/day continued until CD4 counts are >100 cells/mm3 for at least 
6 months.98 Primary prophylaxis with itraconazole has been shown to reduce invasive 
fungal infections in patients with CD4 counts <200 cells/mm3,99 however the strategy has 
not been widely adopted in Asia due to concerns of costs, toxicity, drug resistance and 
interactions.  
 
Conclusions 
 
Serious fungal infections continue to contribute very significantly to HIV-related 
mortality world-wide. For pneumocystosis, talaromycosis, and in particular 
histoplasmosis, affordable, rapid point-of-care diagnostic tests, as have been developed 
for cryptococcosis, are urgently needed. In addition, antifungal drugs, including D-AmB, 
liposomal amphotericin B, and flucytosine, need to be made much more widely available 
100. D-AmB and flucytosine have been recently added to the WHO list of essential 
medicines. Such measures, together with continued international efforts in education and 
training in the management of fungal disease, have the potential to significantly improve 
patient outcomes. 
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Figure 1. A.  CT imaging of a 41 year old female with HIV infection presenting with 
cough and dyspnea.  The imaging demonstrated mixed alveolar and interstitial infiltrates 
that proved on BAL to be due to Pneumocystis jirovecii pneumonia.  B. Methenamine 
silver staining demonstrates typical Pneumocystis organisms clustered in alveolar 
exudates  
 
Figure 2: A. Chest-X ray with a diffuse interstitial reticulonodular pattern in a HIV-
infected patient with histoplasmosis; B. Photograph of a lymph node enlargement in a 
HIV-infected patient with histoplasmosis; C. Photographs of colonic ulcerations in a 
HIV-infected patient with histoplasmosis; D. Giemsa-stained bone marrow smear 
showing the yeast phase of Histoplasma capsulatum; E. Lactophenol blue-stained bone 
marrow culture showing the mold form of Histoplasma capsulatum (Sources: [A & B] Pr 
P. Couppié, [C] Dr D. Louvel, [D&E] Dr C. Aznar from Cayenne General Hospital, 
France)  
 
Figure 3. Geographical distribution of T. marneffei infection 
 
Figure 4. A) Photograph of skin lesions in a HIV-infected patient with talaromycosis, 
used with written consent of the patient; B) Giemsa-stained touch skin smear showing 
oval-shape yeast organisms inside and outside of a ruptured macrophage. The arrowhead 
highlights the midline septum in a dividing yeast cell characteristic of T. marneffei; C) 
Morphology of T. marneffei colonies and T. marneffei cells grew at 25oC and at 37oC on 
Sabouraud agar medium  
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